Images

Filter by

Characteristics of Other Biomarkers for Heart Failure
Characteristics of Other Biomarkers for Heart Failure
Pharmacokinetics of the Natriuretic Peptides
Pharmacokinetics of the Natriuretic Peptides
Figure 2 Activation of the B type Natriuretic Peptide
Figure 2: Activation of the B-type Natriuretic Peptide
Different Potential Biomarkers in the Diagnosis and Management of Heart Failure
Different Potential Biomarkers in the Diagnosis and Management of Heart Failure
Mortality in Natriuretic Peptide Guided Trials in Chronic Heart Failure with Reduced Ejection Fraction
Mortality in Natriuretic Peptide Guided Trials in Chronic Heart Failure with Reduced Ejection Fraction
Medication Intensification
Medication Intensification
Some Criteria of Natriuretic Peptide Guided Trials Including Patients with Heart Failure with Reduced Ejection Fraction
Some Criteria of Natriuretic Peptide Guided Trials Including Patients with Heart Failure with Reduced Ejection Fraction
Factors Influencing Natriuretic Peptide Levels Independent of Heart Failure
Factors Influencing Natriuretic Peptide Levels Independent of Heart Failure
Figure 2 Comparison Between Radiofrequency Catheter Ablation Versus Antiarrhythmic Drugs Treatment
Figure 2: Comparison Between Radiofrequency Catheter Ablation Versus Antiarrhythmic Drugs Treatment
Figure 1 Management of Patients Presenting With Frequent Premature Ventricular Complexes
Figure 1: Management of Patients Presenting With Frequent Premature Ventricular Complexes
Figure 6 Ajmaline Challenge Testing
Figure 6: Ajmaline Challenge Testing
Figure 5 Catecholaminergic Polymorphic Ventricular Tachycardia and Early Repolarisation Syndrome
Figure 5: Catecholaminergic Polymorphic Ventricular Tachycardia and Early Repolarisation Syndrome